Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haferlach, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haferlach, T
Haematologica, Vol 89, Issue 4, 408-418
Copyright © 2004 by Ferrata Storti Foundation

Journal Article

A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group

T Haferlach, W Kern, C Schoch, S Schnittger, MC Sauerland, A Heinecke, T Buchner, W Hiddemann, and

Ludwig-Maximilians-University, University Hospital Grosshadern, Dept. of Internal Medicine III, Munchen, Germany. torsten.haferlach@med3.med.uni-muenchen.de

BACKGROUND AND OBJECTIVES: To refine cytogenetically based risk-stratification in acute myeloid leukemia (AML). DESIGN AND METHODS: Stratification was improved by combining cytogenetics and day 16 bone marrow blasts and by subdividing unfavorable cytogenetics. The new score identifying five prognostically different groups was developed in 321 patients (AMLCG 1992 trial) and subsequently validated in 680 patients (AMLCG 1999 trial). RESULTS: Subgroups defined were: 1) favorable cytogenetics (t(8;21), inv(16)); 2) intermediate cytogenetics (normal karyotype, other abnormalities not rated favorable or unfavorable) and day 16 blasts <10%; 3) intermediate cytogenetics and day 16 blasts >or=10%; 4) unfavorable cytogenetics (-5/5q-, -7/7q-, 3q21q26 aberrations, 11q23 aberrations, 12p-, 17p-) excluding complex aberrations; 5) complex aberrant karyotypes (>or=3 aberrations). In AMLCG 1992 patients significant differences were observed with regard to complete remission (CR) rate (82%, 83%, 58%, 76%, 53%), persistent leukemia (PL) rate (7%, 8%, 33%, 14%, 31%), median event-free survival (EFS; 25, 14, 5, 6, 2 months), median overall survival (OS; not reached, 26, 12, 14, 6 months), and median relapse-free survival (RFS; 26, 19, 13, 8, 4 months). The prospective validation of the score proved its significant power (AMLCG 1999 cohort) with regard to CR (63%, 65%, 51%, 45%, 35%), PL (17%, 18%, 40%, 35%, 48%), median EFS (14, 7, 3, 2, 2 months), median OS (25, 15, 12, 6, 4 months), and median RFS (not reached, 15, 10, 8, 5 months). INTERPRETATION AND CONCLUSIONS: This new prognostic score provides a highly valuable tool for future clinical trials in AML focusing on distinct and subgroup-specific treatment effects.


This article has been cited by other articles:


Home page
 JCOHome page
C. D. Baldus, P. Martus, T. Burmeister, S. Schwartz, N. Gokbuget, C. D. Bloomfield, D. Hoelzer, E. Thiel, and W. K. Hofmann
Low ERG and BAALC Expression Identifies a New Subgroup of Adult Acute T-Lymphoblastic Leukemia With a Highly Favorable Outcome
J. Clin. Oncol., August 20, 2007; 25(24): 3739 - 3745.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. D. Baldus, C. Thiede, S. Soucek, C. D. Bloomfield, E. Thiel, and G. Ehninger
BAALC Expression and FLT3 Internal Tandem Duplication Mutations in Acute Myeloid Leukemia Patients With Normal Cytogenetics: Prognostic Implications
J. Clin. Oncol., February 10, 2006; 24(5): 790 - 797.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.